NASDAQ: BCYC | Healthcare / Biotechnology / United Kingdom |
14.40 | +0.8800 | +6.51% | Vol 464.61K | 1Y Perf -53.31% |
Nov 30th, 2023 16:00 DELAYED |
BID | 13.50 | ASK | 16.25 | ||
Open | 14.50 | Previous Close | 13.52 | ||
Pre-Market | - | After-Market | 14.40 | ||
- - | - -% |
Target Price | 54.57 | Analyst Rating | Strong Buy 1.23 | |
Potential % | 278.96 | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ★★★+ 53.82 | |
Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | — - | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 8.88 | Earnings Rating | Strong Buy | |
Market Cap | 610.87M | Earnings Date | 2nd Nov 2023 | |
Alpha | 0.01 | Standard Deviation | 0.19 | |
Beta | 0.82 |
Today's Price Range 14.3115.36 | 52W Range 12.5433.49 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | 4.05% | ||
1 Month | -6.19% | ||
3 Months | -35.19% | ||
6 Months | -40.74% | ||
1 Year | -53.31% | ||
3 Years | -29.31% | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -35.52 | |||
ROE last 12 Months | -46.42 | |||
ROA (5Y Avg) | -8.69 | |||
ROA last 12 Months | -30.75 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -37.45 | |||
Return on invested Capital Q | -8.55 | |||
Return on invested Capital Y | -5.82 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-9.20 | ||||
3.22 | ||||
79.58 | ||||
- | ||||
-12.70 | ||||
-2.24 | ||||
3.22 | ||||
9.75 | ||||
613.93M | ||||
Forward PE | -2.48 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
9.00 | ||||
9.20 | ||||
0.12 | ||||
0.15 | ||||
-29.70 | ||||
Leverage Ratio | 1.40 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
-659.80 | ||||
-641.80 | ||||
-464.40 | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
11.28M | ||||
0.38 | ||||
- | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2023 | -1.06 | -1.26 | -18.87 |
Q02 2023 | -1.10 | -1.41 | -28.18 |
Q01 2023 | -1.06 | -1.30 | -22.64 |
Q04 2022 | -1.06 | -1.01 | 4.72 |
Q03 2022 | -0.98 | -0.96 | 2.04 |
Q02 2022 | -0.82 | -0.90 | -9.76 |
Q01 2022 | -0.70 | -0.93 | -32.86 |
Q04 2021 | -0.60 | -0.63 | -5.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2023 QR | -1.23 | 9.56 | Positive |
12/2023 FY | -5.27 | -0.38 | Negative |
3/2024 QR | -1.21 | 12.95 | Positive |
12/2024 FY | -5.56 | 6.55 | Positive |
Next Report Date | - |
Estimated EPS Next Report | -1.06 |
Estimates Count | 8 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 464.61K |
Shares Outstanding | 42.42K |
Shares Float | 1.88M |
Trades Count | 4.96K |
Dollar Volume | 6.86M |
Avg. Volume | 300.53K |
Avg. Weekly Volume | 194.10K |
Avg. Monthly Volume | 391.48K |
Avg. Quarterly Volume | 316.01K |
Bicycle Therapeutics plc (NASDAQ: BCYC) stock closed at 14.4 per share at the end of the most recent trading day (a 6.51% change compared to the prior day closing price) with a volume of 464.61K shares and market capitalization of 610.86M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 81 people. Bicycle Therapeutics plc CEO is Kevin Lee.
The one-year performance of Bicycle Therapeutics plc stock is -53.31%, while year-to-date (YTD) performance is -51.35%. BCYC stock has a five-year performance of %. Its 52-week range is between 12.54 and 33.49, which gives BCYC stock a 52-week price range ratio of 8.88%
Bicycle Therapeutics plc currently has a PE ratio of -9.20, a price-to-book (PB) ratio of 3.22, a price-to-sale (PS) ratio of 79.58, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -30.75%, a ROC of -37.45% and a ROE of -46.42%. The company’s profit margin is -%, its EBITDA margin is -641.80%, and its revenue ttm is $11.28 Million , which makes it $0.38 revenue per share.
Of the last four earnings reports from Bicycle Therapeutics plc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.06 for the next earnings report. Bicycle Therapeutics plc’s next earnings report date is -.
The consensus rating of Wall Street analysts for Bicycle Therapeutics plc is Strong Buy (1.23), with a target price of $54.57, which is +278.96% compared to the current price. The earnings rating for Bicycle Therapeutics plc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bicycle Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bicycle Therapeutics plc has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.40, ATR14 : 1.16, CCI20 : 29.95, Chaikin Money Flow : -0.15, MACD : -0.88, Money Flow Index : 40.79, ROC : 8.35, RSI : 45.08, STOCH (14,3) : 58.13, STOCH RSI : 1.00, UO : 43.63, Williams %R : -41.88), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bicycle Therapeutics plc in the last 12-months were: Alistair Milnes (Sold 2 248 shares of value $61 773 ), Crockett Nigel (Sold 3 141 shares of value $81 933 ), Dominic Smethurst (Sold 1 801 shares of value $52 337 ), Keen Nicholas (Sold 2 744 shares of value $73 410 ), Kevin Lee (Sold 7 486 shares of value $205 729 ), Lee H. Kalowski (Sold 2 191 shares of value $60 681 ), Lee Kevin (Sold 10 454 shares of value $272 729 ), Michael Skynner (Sold 2 248 shares of value $61 773 ), Milnes Alistair (Sold 3 141 shares of value $81 933 ), Nicholas Keen (Sold 2 136 shares of value $59 536 ), Nigel Crockett (Sold 2 248 shares of value $61 773 ), Skynner Michael (Sold 3 141 shares of value $81 933 ), Smethurst Dominic (Sold 1 801 shares of value $52 337 ), Thompson Travis Alvin (Sold 61 shares of value $1 531 ), Travis Alvin Thompson (Sold 54 shares of value $1 080 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.
CEO: Kevin Lee
Telephone: +44 1223261503
Address: B900, Babraham Research Campus, Cambridge CB22 3AT, , GB
Number of employees: 81
Tue, 12 Sep 2023 04:25 GMT Bicycle Therapeutics (BCYC) Gets a Buy from JMP Securities
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.